Literature DB >> 20565561

Infantile haemangiomas: a challenge in paediatric dermatology.

R A Schwartz1, M I Sidor, M L Musumeci, R L Lin, G Micali.   

Abstract

Infantile haemangiomas, common benign vascular tumours of childhood, are characterized by rapid growth during the first year of life and a slow regression that is usually completed at 7-10 years of age. These tumours are composed of endothelial cells with high mitotic rates and stromal components such as fibroblasts, mast cells and pericytes. Haemangiomas become a challenge when they are part of a syndrome, are located in certain areas of the body or when complications develop. The above-mentioned factors also influence the treatment modality used. However, although there remain many uncertainties regarding management, the beta-adrenergic receptor blocker propranolol is a promising new candidate for first-line systemic therapy. It produces such a dramatic and rapid response that the appearance of an infantile haemangioma should impart expeditious consideration of the risks and benefits of its use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20565561     DOI: 10.1111/j.1468-3083.2010.03650.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  12 in total

1.  Efficacy and Safety of 2% Topical Propranolol Cream for the Treatment of Proliferating Infantile Strawberry Hemangiomas.

Authors:  Yuanyuan Wang; Xingcun Zhang; Yadong Yang; Junbo Zhang; Yunchuan Yang; Yuangang Lu
Journal:  Indian J Pediatr       Date:  2017-02-14       Impact factor: 1.967

2.  Distribution of propranolol in periocular tissues: a comparison of topical and systemic administration.

Authors:  Jinsong Hao; Michael B Yang; Hongzhuo Liu; S Kevin Li
Journal:  J Ocul Pharmacol Ther       Date:  2011-08-02       Impact factor: 2.671

3.  Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial.

Authors:  Kyu Han Kim; Tae Hyun Choi; Yunhee Choi; Young Woon Park; Ki Yong Hong; Dong Young Kim; Yun Seon Choe; Hyunjung Lee; Jung-Eun Cheon; Jung-Bin Park; Kyung Duk Park; Hyoung Jin Kang; Hee Young Shin; Jae Hoon Jeong
Journal:  JAMA Dermatol       Date:  2017-06-01       Impact factor: 10.282

4.  Propranolol treatment of complicated hemangiomas.

Authors:  Derya Ozyörük; Emine Zengin
Journal:  Indian J Pediatr       Date:  2013-07-06       Impact factor: 1.967

5.  Clinical efficacy of propranolol in the treatment of hemangioma and changes in serum VEGF, bFGF and MMP-9.

Authors:  Shanying Wu; Biao Wang; Lifen Chen; Shuyuan Xiong; Fulian Zhuang; Xunlei Huang; Meishui Wang; Zugen Huang
Journal:  Exp Ther Med       Date:  2015-07-20       Impact factor: 2.447

Review 6.  Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?

Authors:  Laura Macca; Domenica Altavilla; Luca Di Bartolomeo; Natasha Irrera; Francesco Borgia; Federica Li Pomi; Federico Vaccaro; Violetta Squadrito; Francesco Squadrito; Mario Vaccaro
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

7.  Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital.

Authors:  Pauline McGee; Sophie Miller; Claire Black; Susannah Hoey
Journal:  Ulster Med J       Date:  2013-01

8.  Propranolol: Effectiveness and Failure in Infantile Cutaneous Hemangiomas.

Authors:  Andrea Domenico Praticò; Filippo Caraci; Piero Pavone; Raffaele Falsaperla; Filippo Drago; Martino Ruggieri
Journal:  Drug Saf Case Rep       Date:  2015-12

9.  Intense pulsed-light therapy for proliferative haemangiomas of infancy.

Authors:  Marie Caucanas; Philippe Paquet; Frédérique Henry; Claudine Piérard-Franchimont; Marie-Annick Reginster; Gérald E Piérard
Journal:  Case Rep Dermatol Med       Date:  2011-12-27

10.  Propranolol induces hemangioma endothelial cell apoptosis via a p53‑BAX mediated pathway.

Authors:  Tian-Hua Yao; Parekejiang Pataer; Krishna Prasad Regmi; Xi-Wen Gu; Quan-Yan Li; Jing-Ting Du; Su-Meng Ge; Jun-Bo Tu
Journal:  Mol Med Rep       Date:  2018-05-14       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.